SCHEMBL1980248

SCHEMBL1980248

Oc1cccc2c1Cc1ccccc1O2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.59
MAOB P27338 2/20 0.59
DRD2 P14416 2/20 0.45
DRD3 P35462 2/20 0.45
DRD1 P21728 1/20 0.45
DRD5 P21918 1/20 0.45
CA2 P00918 3/20 0.42
CA4 P22748 3/20 0.42
CA1 P00915 2/20 0.42
CA6 P23280 2/20 0.42
BCL2L1 Q07817 1/20 0.42
BAD Q92934 1/20 0.42
MAPKAPK2 P49137 2/20 0.42
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 2/20 0.37
MAPT P10636 2/20 0.37
ALOX15 P16050 2/20 0.37
HSD17B10 Q99714 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6129306 0.98 MAOA (0.57) MAOAMAOBDRD2DRD3DRD1
SCHEMBL7970202 0.81 MAOA (0.55) MAOAMAOBDRD2DRD3DRD1
SCHEMBL30346211 0.80 MAOA (0.53) MAOAMAOBCA2CA4CA1
SCHEMBL8649269 0.80 MAOA (0.53) MAOAMAOBCA2CA4CA1
SCHEMBL4809975 0.79 DRD2 (0.47) MAOAMAOBDRD2DRD3DRD1
SCHEMBL1979793 0.79 MAOA (0.52) MAOAMAOBCA2CA4CA1
Xanthene SCHEMBL2312744 0.79 MAOA (0.94) MAOAMAOBMAPKAPK2GAANPSR1
SCHEMBL5605804 0.78 MAOA (0.50) MAOAMAOBDRD2DRD3DRD1
SCHEMBL31545621 0.77 MAOA (0.46) MAOAMAOBCA2CA4CA1
SCHEMBL5094900 0.77 MAOA (0.59) MAOAMAOBDRD2DRD3DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102573469-A Na/K-ATP enzyme ligand, ouabain G antagonist, test method and application thereof UNIV TOLEDO 2012-07-11 CN claimed
EP-0471794-B1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES OKLAHOMA MED RES FOUND (US) 1996-10-02 EP claimed
EP-0471794-A4 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES 1992-05-06 EP claimed
EP-0471794-A1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES. OKLAHOMA MED RES FOUND (US) 1992-02-26 EP claimed
WO-1990013296-A1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 1990-11-15 WO claimed
JP-8151327-A None JP disclosed
US-20240358861-A1 COMPOSITIONS AND METHODS OF FLUORESCEIN SODIUM FOR EARLY DIAGNOSIS OF CERVICAL CANCER THE MOEIN FAMILY TRUST (US) 2024-10-31 US disclosed
EP-2879656-B2 DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE OREAL (FR) 2024-07-17 EP disclosed
US-11730682-B2 Self-standing cosmetic sheet L'OREAL (FR) 2023-08-22 US disclosed
CN-110869340-B Process for the production of 3, 7-dimethyl-9- (2, 6-trimethyl-1-cyclohexen-1-yl) -non-2E, 7E-diene-4-yne-1, 6-diol 帝斯曼知识产权资产管理有限公司 2022-10-14 CN disclosed
EP-2836187-B1 SELF-STANDING COSMETIC SHEET OREAL (FR) 2021-12-08 EP disclosed
EP-3395323-B1 METHOD FOR TREATING HAIR KAO CORP (JP) 2021-09-29 EP disclosed
EP-0471794-A1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES. OKLAHOMA MED RES FOUND (US) 1992-02-26 EP disclosed
EP-0110682-B1 ACTIVATED ARYL CAPPED FLUORESCENT COMPOUNDS, AND ASSAY METHODS AND SYSTEMS USING THEM AS FLUOROGENIC PRECURSORS SYVA COMPANY (US) 1991-08-21 EP disclosed
WO-1990013296-A1 ANTIVIRAL THERAPY USING THIAZINE AND XANTHENE DYES OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 1990-11-15 WO disclosed
US-4857455-A WATER SOLUBLE ACTIVATED CAPPED AROMATIC FLUORESCENT COMPOUNDS SYNTEX (U.S.A) INC. (US) 1989-08-15 US disclosed
EP-0311010-A2 Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1989-04-12 EP disclosed
EP-0110682-A2 Activated aryl capped fluorescent compounds, and assay methods and systems using them as fluorogenic precursors SYVA COMPANY (US) 1984-06-13 EP disclosed
US-4268514-A ANALGESICS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1981-05-19 US disclosed
US-3931298-A FROM A HYDROXYAROMATIC AND AMMONIA, GROUP 8-CYCLOHEXANONE CATALYST ETHYL CORPORATION (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730682-B2 Self-standing cosmetic sheet CUTA, DSG1, SUCLG1 MAOA 1465/4885MAOB 3142/4885DRD2 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.